Clinical efficacy of transurethral plasmakinetic enucleation and resection of the prostate (PKERP) in the treatment of benign prostatic hyperplasia

Abstract

Objective To investigate the efficacy and complications of transurethral plasmakinetic enucleation and resection of the prostate (PKERP) and plasmakinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH). Methods The clinical data of 120 patients with BPH who were treated in our hospital from January 2015 to January 2018 were analyzed, 60 cases treated with PKRP as the control group, 60 cases treated with PKERP as the study group. The maximal urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), residual urine volume (RUV), and complications were compared between the two groups. Results The Qmax, IPSS, and RUV of the study group were better than those of the control group (P<0.05). The incidence of total complications in the study group was 6.66%, lower than that in the control group (23.33%) (P<0.05). Conclusion PKERP in the treatment of BPH could effectively improve urethral function and prostate function, with fewer postoperative complications, which could be widely used in clinical practice. Key words: Transurethral plasmakinetic enucleation and resection of the prostate (PKERP); Benign prostatic hyperplasia (BPH); Plasmakinetic resection of the prostate (PKRP)